Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cixutumumab and Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
NCT01614795Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2012
- Primary completion
- Apr 2014
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of cixutumumab, temsirolimus in osteosarcoma (OS), Ewing sarcoma, rhabdomyosarcoma (RMS), soft tissue sarcoma (STS), sponsored by National Cancer Institute. Started Jun 2012; status: completed.
02
Drugs
cixutumumabtemsirolimus
03
Conditions
osteosarcoma (OS)Ewing sarcomarhabdomyosarcoma (RMS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT01614795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01614795.